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Anaplastic thyroid cancer is one of the most aggressive human malignancies and the outcomes of conventional therapy have been far
from satisfactory. Recently, epidermal growth factor receptor (EGFR)-targeted therapy has been introduced as an alternative
therapeutic strategy for highly malignant cancers. This study was undertaken to investigate the expression of EGFR in anaplastic
thyroid cancer cell lines, and to explore the potential of therapies targeting EGFR as a new therapeutic approach. EGFR was
universally expressed in anaplastic cancer cell lines at a variety of levels. Specific EGFR stimulation with epidermal growth factor
showed significant phosphorylation of ERK1/2 and Akt, and resulted in marked growth stimulation in an anaplastic thyroid cancer cell
line, which highly expressed EGFR. This EGFR-transmitted proliferation effect of the cancer cell line was completely inhibited by
gefitinib, an EGFR tyrosine kinase inhibitor. Moreover, growth of xenografts inoculated in mice was inhibited in a dose-dependent
manner with 25–50mgkg
 1 of gefitinib administrated orally. Inhibition of EGFR-transmitted growth stimulation by gefitinib was
clearly observed in anaplastic thyroid cancer cell lines. Our results suggested that EGFR-targeted therapy, such as gefitinib, might be
worth further investigation for the treatment of anaplastic thyroid cancer.
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Anaplastic thyroid carcinoma, one of the most aggressive human
malignancies, shows rapid invasive growth to the surrounding
tissues and often demonstrates metastatic disease in the distant
organs. In such cases, surgery alone is not enough and a
combination therapy with chemotherapy and radiation is essential,
yet the outcome of such intensive multimodal therapy is far from
satisfactory. The majority of patients with anaplastic thyroid
cancer die within a year after receiving an initial diagnosis
(Volante et al, 2004). Different therapeutic approaches have been
explored but the results are disappointing, and the prognosis has
not changed over the past decades. Thus, a novel therapeutic
approach is highly desirable.
The epidermal growth factor receptor (EGFR) is a cell
membrane receptor that plays a key role in cancer development
and progression. Increasing evidence has shown that the over-
expression of EGFR closely correlates with advanced tumour stage
and metastasis, and poor clinical outcome in many human cancers
including breast, cervix, lung, bladder, and head and neck (Iihara
et al, 1993; Hu et al, 1997; Grandis et al, 1998; Brabender et al,
2001; Arteaga and Truica, 2004). An EGFR can be stimulated upon
interaction with corresponding ligands such as epidermal growth
factor (EGF) or transforming growth factor-a (Ullrich and
Schlessinger, 1990). Ligand binding to EGFR induces dimerisation
of the receptor. Homo and/or heterodimerisation of EGFR
activates intrinsic tyrosine kinase, leading to receptor autopho-
sphorylation, then activates a number of intracellular signal
transducing elements (Raymond et al, 2000). Phosphatidylinosi-
tol-30-kinase, protein kinase B/AKT (Akt), a small G-protein (ras)
the ras GTPase-activating protein, extracellular signal-regulated
kinase (ERK) 1/2, Src family kinase, and STATs mediated pathway
are the known downstream effecters of the EGFR. A cell-
proliferating signal from the activated EGFR reaches ERK1/2
through ras/raf activation, and is transmitted to intranucleus cell
proliferation signals. Akt also transmits the signal from activated
EGFR to inhibit apoptosis.
Recently, molecular-targeted therapy has attracted attention.
Many kinds of EGFR-targeted molecular treatments have been
attempted, such as antireceptor monoclonal antibodies, antiligand
monoclonal antibodies, ligand–toxin conjugates, scFv–toxin
conjugates, ligand–genistein conjugates and tyrosine kinase
inhibitors (Raymond et al, 2000). Among these, gefitinib (‘Iressa’,
ZD1839) is an orally active EGFR tyrosine kinase inhibitor, which
blocks EGFR signal transduction pathways. Antitumour activity of
gefitinib has been shown in experimental animal models (Sirotnak,
2003) and tumour cell lines (Campiglio et al, 2004). Gefitinib has
demonstrated significant antitumour activity in two phase II trials
in advanced non-small-cell lung cancer (NSCLC), and is now
approved for this indication in many markets around the world
(Fukuoka et al, 2003; Kris et al, 2003).
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anaplastic thyroid cancer cell lines and explored the potential
therapeutic benefits of targeting this molecule with gefitinib.
MATERIALS AND METHODS
Chemicals
Gefitinib (Iressa, ZD1839) was provided by AstraZeneca (Maccles-
field, UK).
Cell lines and cell cultures
We used five human undifferentiated thyroid cancer cell lines
(OCUT-1, -2, TTA-1, KTC-1 and ACT-1). OCUT-1 (Ogisawa et al,
2002) and -2 were recently established and characterised in our
laboratory. OCUT-2 was established from cancerous fluid in the
thoracic cavity of an 81-year-old Japanese woman with anaplastic
thyroid cancer. This cell line was passed over 100 passages, grown
stably and maintained over 2 years from the initial primary
culture. TTA-1, KTC-1 and ACT-1 were each kindly provided by
Dr A Yoshida of Kanagawa Cancer Center, Dr J Kurebayashi of
Kawasaki Medical College and Dr S Ohata of Tokushima
University, respectively. Each cell line was cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100IUml
 1 of penicillin and 100mgml
 1 of
streptomycin at 371C with 5% CO2 in a humidified condition.
Reverse transcription–polymerase chain reaction
We determined the expression of EGFR mRNA by reverse
transcription–polymerase chain reaction (RT–PCR) as reported
previously (Ogisawa et al, 2002). Briefly, total RNA was collected
from samples using Trizol reagent (Life Technologies, Inc.,
Gaithersburg, MD, USA). Total RNA (1ng) was reverse-tran-
scripted in 20ml of reaction buffer containing 1ml of oligo dT
primer, 4mlo f5 RNA PCR buffer, 1mlo f1 0m M dNTPs, 2mlo f
0.1 M DTT, 0.5ml of RNA guard (Amersham Pharmacia Biotech,
Buckinghamshire, UK) and 1ml of Moloney murine leukemia virus
reverse transcriptase (Life Technologies). cDNA samples were
amplified in 20ml of PCR reaction mixture with each primer set
and Taq-polymerase (AmpliTaq Gold, Applied Biosystems, Tokyo,
Japan). The primers used for EGFR were 50-CGC TGC TGG CTG
CGC TCT G-30,5 0-CCT CCT GGA TGG TCT TTA T-30 (Ullrich et al,
1984). Reverse transcription–polymerase chain reaction efficiency
was confirmed by amplifying human glyceraldehydes-3-phosphate
dehydrogenase (GAPDH), using the primers 50-ACC ACA GTC
ATG CCA TCA C-30 and 50-TCC ACC ACC CTG TTG CTG TA-30.
PCR conditions were 941C for 3min, followed by 30 cycles of 941C
for 30s, 651C for 30s and 721C for 30s. Amplified products were
electrophoresed on 2% agarose gel, stained with ethidium
bromide.
Flow cytometry
Expression of EGFR on the cell surface was measured by flow
cytometry (Zhang et al, 2004). Five cell lines were plated in 100mm
dishes. Cells were left for 48h to grow to semiconfluency then lifted
with trypsin treatment and aliquoted into two sets of tubes
(1 10
6cells/tubes), and washed twice with cold FACS buffer
(0.03% sodium azide, 0.3% bovine serum albumin in phosphate-
buffered saline (PBS)). One set of cells was treated with 200mgml
 1
of EGFR monoclonal antibody (F0797 DAKO). Cells not treated
with monoclonal antibody were used as a control. All incubations
were performed for 30min in the dark on ice. Samples were again
washed with cold FACS buffer, and incubated with 2mgo f
fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG
(Chemicon Int. Inc., Temecula, CA, USA) in 200ml of FACS buffer
for 30min on ice. After washing again with FACS buffer, FITC-
labelled cells were scanned using a FACS/Calibur Flow Cytometer
(Becton Dickinson, Mountain View, CA, USA).
MTT assay
The inhibitory effects of gefitinib on the viability of these cell lines
were measured by MTT assay (Chung et al, 2002). Cells (1 10
4)
were seeded in each well of a 96-well plastic culture plate and left
overnight under the same conditions. They were then treated with
the intended doses of gefitinib for 3 days. After the incubation
period, MTT was added to the final concentration of 0.5mgml
 1,
and the cells were incubated again for 2h under the same
conditions. The culture plate was centrifuged at 200 g for 5min
and the supernatant was removed. Dimethyl sulphoxide was added
for reaction, and the absorbency was measured with a microplate
reader (Model 550, Bio-Rad Laboratories, Hercues, CA, USA) and
calculated using the supplied software. The experiments were
carried out three times independently, in triplicate each time, and
the average values of the three independent experiments were
calculated.
Effect of gefitinib on tumour cell proliferation under EGF
stimulation in vitro
Approximately 4 10
4 cells were spread onto a 10-mm plastic dish
and left overnight. Then the cells were cultured for 48h in DMEM
without FBS. In total, 1nmol of EGF (#26190U, Upstate, Lake
Placid, NY, USA) was added to a plate to stimulate the EGFR of the
cells. The efficacy of gefitinib (10 and 100nM) or neutralising
antibody (#26190U, Upstate) was investigated by adding them to
EGF. The number of cells was counted after 48h of incubation.
Experiments were carried out independently in triplicate.
Western blotting
Expression of the protein in the signal transduction pathway was
measured by Western blot analysis (Ono et al,2 0 0 4 ) .C e l l sw e r e
incubated for 48h supplemented with EGF (1nM), or EGF (1nM)
and gefitinib (10 or 100nM) as explained above. After the treatment,
cells (1 10
6) were lysed in 200ml of 1% triton X in PBS and gently
shaken for 20min, the protein was then extracted by centrifugation
at 8050 g for 10min at 41C. Protein concentration was measured
and total protein (60mg) was electrophoresed on a 10% poly-
acrylamide gel and transferred onto a PVDF membrane (Hybond P,
Amersham Pharmacia Biotech). The membrane was blocked with
5% skim milk for 2h at room temperature, and incubated with
1:1000 dilution of p44/42 MAP kinase and phospho-p44/42 MAP
kinase rabbit antibody (# 9101, 9102 Cell Signaling technology) or
1:1000 dilution of Akt and phospho-Akt rabbit antibody (# 9271,
9272 Cell Signaling Technology) for 12h at 41C. After three washings
with 0.1% Tween 20 in PBS for 10min each at room temperature,
the membrane was incubated for 1h at room temperature with
peroxidase-conjugated secondary antibody (AP181P, Chemicon
International, Inc., Temecula, CA, USA), and again washed five
times with PBS under the same conditions. Peroxidase activity of the
secondary antibody was detected with an enhanced chemi-
luminescence detection system (ECL Plus Western Blotting Detec-
tion System, Amersham Pharmacia Biotech).
In vivo experiment to confirm the efficacy of gefitinib in
xenografts of cancer cells
Female balb/ca Jcl-nu mice, 4 weeks old, was purchased from
Japanese Kurea Co., Osaka, Japan. The ethical issues of the
experiment were approved by the Animal Research Committee of
Osaka City University Graduate School of Medicine, and the
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lines. Mice were acclimatised at the Animal Facility of Osaka City
University Graduate School of Medicine for 1 week. Then, mice
were injected subcutaneously with 10
7 ACT-1 or OCUT-2 cells into
the dorsal flank under anaesthesia. After 7 days, when established
tumours of approximately 3–4mm in diameter were detected,
mice were assigned to one of three treatment groups (n¼8 in each
group). Each group of mice were administered with 0, 25 or
50mgkg
 1 of gefitinib p.o. once a day on days 1–5 each week for 4
weeks as a ball-milled suspension in 0.5% (vv
 1) polysolvate 80
(Wakeling et al, 2002). The mice were monitored daily for signs of
toxicity and were weighed regularly. Tumour size was measured
using the formula p/6 larger diameter (smaller diameter)
2,a s
reported previously (Ciardiello et al, 2000).
Immunohistochemistry
Immunoreactivity for EGFR and CD34 was determined by the
streptoavidin–biotin method. Formalin-fixed, paraffin-embedded
tissue blocks were obtained by xenograft. An immunohistochem-
ical study was performed as described previously (Ogisawa et al,
2002). Briefly, sections were dewaxed, microwave pretreated and
incubated with 0.3% hydrogen peroxide in methanol for 30min.
After blocking to reduce nonspecific antibody binding, polyclonal
rabbit anti-human EGFR antibody (Santa Cruze Biotechnology,
Santa Cruze, CA, USA) (Hirata et al, 2004) and monoclonal
antibody against CD34 (DAKO M7168) were reacted with tissue
sections at room temperature for 2h followed by three washes with
PBS. The sections were incubated with secondary antibody, and
then reacted with streptoavidin–biotin peroxidase regent (HIS-
TOFINE KIT, Nichirei Co., Tokyo, Japan). Finally, diaminobenzi-
dine and 1% hydrogen peroxidase were applied as chromogen,
counterstained with haematoxyline.
RESULTS
Expression of EGFR and effects of gefitinib on cell viability
in cancer cells
Expression of EGFR mRNA and protein was observed in every cell
line examined (Figure 1). The level of EGFR expression varied and
was lowest in OCUT-2 compared with other cell lines. High-level
expression of EGFR was shown in both ACT-1 and TTA-1 cell lines
(Figure 2). There was no correlation between the level of mRNA
and protein expression. Dose-dependent effects of gefitinib on cell
viability were observed in every cell line examined under normal
culture conditions with 10% FBS. The inhibitory effect of gefitinib
on cell viability was more prominent in the ACT-1 cell line, which
overexpressed EGFR, than the OCUT-2 cell line, which expressed
low levels of EGFR (Figure 3). However, even for the EGFR-
overexpressing cell line, ACT-1, high concentrations of gefitinib
(410mM) were required to display a significant effect on cell
viability in the presence of FBS. We could not maintain the cells
without existence of FBS for more than 72h, and could not get any
reliable data from the similar MTT assays without FBS. Thus, we
investigated the effect of gefitinib on EGF stimulation.
Effect of gefitinib on tumour cell proliferation under EGF
stimulation
The effect of gefitinib on cancer cell proliferation under
EGF stimulation was investigated in two cell lines (OCUT-2 and
Control
GE GE
OCUT-1
GE GE G E GE
OCUT-2 ACT-1 KTC-1 TTA-1
216 bp
247bp
Figure 1 Expression of EGFR mRNA was determined by RT–PCR. A clear EGFR mRNA expression was observed in every cell line examined. ‘G’ and ‘E’
represented GAPDH and EGFR transcript, respectively. Oesophageal cancer cell line TE-1 was used for positive control.
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Figure 2 Expression of EGFR on the cellular surface was determined by flow cytometric analysis. The levels of EGFR expression in each cell lines varied.
Expression level was the lowest in OCUT-2 compared with other cell lines. High-level expression of EGFR was shown in ACT-1, KTC-1 and TTA-1 cell line.
There was no correlation between the level of mRNA and protein expression.
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which faintly expressed EGFR (Figure 4A). No significant
inhibition of gefitinib upon cell growth was observed in OCUT-
2. In contrast, a marked stimulatory effect of EGF on cell
proliferation was displayed in the ACT-1 cell line, which
overexpressed EGFR (Figure 4B). An inhibitory effect of gefitinib
on ACT-1 cell growth stimulated by EGF was recognised in a dose-
dependent manner. The dose of gefitinib required to inhibit the
effect of EGF stimulation was as low as 100nM and was as effective
as EGF neutralisation. Moreover, gefitinib itself did not inhibit
ACT-1 cell growth in the absence of EGF, suggesting that the
growth inhibitory effect of gefitinib was mainly presented through
inhibition of the EGFR-mediated cell-proliferative pathway.
Effect of gefitinib on phosphorylation of ERK1/2 and Akt
Figure 5 shows the result of Western blot analysis. EGF-induced
phosphorylation of ERK1/2 and Akt was clearly observed in the
ACT-1 cell line. However, in the OCUT-2 cell line, no evident
phosphorylation of ERK1/2 and Akt was observed by EGF
stimulation. The inhibitory effect of gefitinib on EGF-induced
phosphorylation of ERK1/2 was significantly observed in the ACT-
1 cell line. The phosphorylation of ERK1/2 was almost completely
inhibited in this cell line. The phosphorylation of Akt was also
inhibited by gefitinib in the ACT-1 cell line overexpressing EGFR.
Effect of gefitinib on the growth of xenografts in nude mice
As shown in Figure 6, a marked growth inhibition of xenografts
was found in gefitinib-treated mice. This effect was dose
dependent. Growth of the xenograft of ACT-1 cells was almost
completely suppressed with gefitinib after the 4-week treatment
period with a dose of 50mgkg
 1. On the other hand, no significant
effect of gefitinib administration on the growth of the xenograft of
OCUT-2 cells was observed. A reversible mild reduction in body
weight was the only side effect observed with the highest dose
used. Histological specimens showed marked central necrosis and
fibrosis between the cancer cells in xenografts of the ACT-1 cells
resected from gefitinib-treated mice though the size was much
smaller than that observed in the control group. Immunoreactivity
of EGFR on the cells was diminished in xenografts resected from
gefitinib-treated mice. CD34-reactive microvessels were universally
seen between the viable cancer cells in every xenograft and the
density of microvessels did not differ regardless of gefitinib
treatment. However, as shown in Figure 7, morphological change
of microvessels was demonstrated with gefitinib treatment only in
the xenograft of ACT-1. Microvessels in the control group had
thicker walls of a wider diameter than those of the gefitinib-treated
group. Microvessels in the gefitinib-treated group were scattered
between the increased fibrous bands in the xenograft of ACT-1. In
contrast, these morphological changes of the tumour vessels were
not observed in the xenograft of OCUT-2.
DISCUSSION
In the present study, we demonstrated that EGFR was almost
universally expressed in anaplastic thyroid cancer cell lines, and
that the level of its expression varied. Previous studies by
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Figure 3 Efficacy of gefitinib on cell viability was determined by MTT
methodology. Inhibitory effects of gefitinib were observed in every cell line
examined under normal culture conditions with 10% FBS. The inhibitory
effect was most significantly found in the ACT-1 cell line (closed square),
which overexpresses EGFR, than in the OCUT-2 cell line (open circle),
which expresses the lowest level of EGFR of all the cell lines. High
concentrations of gefitinib (410mM) were required to display a significant
adverse effect on cell viability in the presence of FBS.
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Figure 4 The effect of gefitinib on cancer cell proliferation under EGF
stimulation was investigated in two cell lines (OCUT-2 and ACT-1). The
number of cells was counted after 48h following EGF stimulation. Although
no stimulatory effect of EGF was displayed in OCUT-2 (A), which faintly
expresses EGFR, a marked stimulatory effect of EGF on cell proliferation
was displayed in the ACT-1 cell line (B), which overexpresses EGFR. A
significant inhibitory effect of gefitinib on growth stimulation by EGF was
recognised in a dose-dependent manner in ACT-1. The dose of gefitinib
required to inhibit the effect of EGF stimulation was as low as 100nM, and
was as effective as EGF neutralisation.
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that EGFR was frequently overexpressed in anaplastic thyroid
cancer (Di Carlo et al, 1990; Westermark et al, 1996). Moreover, in
those patients whose thyroid tumours bound more EGF, the
prognosis was reported to be poor (Duh et al, 1985). These results
suggested that EGFR plays a role in determining the malignant
potential of the anaplastic thyroid cancer. Recently, EGFR-targeted
molecular treatment with tyrosine kinase inhibitors, including
gefitinib, has shown significant antitumour activity in clinical trials
in advanced NSCLC, with early encouraging clinical data reported
in cancer of the head and neck, colon, and breast (Caponigro,
2004). Patients recruited in these trials have failed initial
chemotherapy. Therefore, these studies provide a new perspective
0
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Figure 5 Effect of gefitinib on phosphorylation of ERK1/2 and Akt was shown by Western blot analysis. EGF-induced phosphorylation of ERK1/2 and Akt
was clearly observed in the ACT-1 cell line. The inhibitory effect of gefitinib on EGF-induced phosphorylation of ERK1/2 was significantly observed in the
ACT-1 cell line. The phosphorylation of ERK1/2 was almost completely inhibited in this cell line. The phosphorylation of Akt was also inhibited by gefitinib in
the ACT-1 cell line overexpressing EGFR.
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Figure 6 Effects of gefitinib on the growth of xenografts in nude mice
was investigated. (A) A marked growth inhibition of xenografts of the
ACT-1 cell was found in gefitinib-treated mice. Growth of xenografts of the
ACT-1 cell was almost completely suppressed by gefitinib at the end of the
4-week treatment period with a dose level of 50mgkg
 1.( B)N o
significant growth inhibitory effect of gefitinib was found on the xenografts
of the OCUT-2 cell.
Figure 7 Representative results of immunohistochemistry against CD34
in the xenograft inoculated on the mice. Microvessels in the control group
have a thicker wall with wider diameter (A) than that of the gefitinib-
treated group (B). Both images are shown at  400 magnification
originally.
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anaplastic thyroid cancer.
In the present study, however, we could not show significant
effects of gefitinib in vitro with the normal culture conditions with
FBS, initially. In this condition, EGF level in the culture medium
was as low as undetectable level (data not shown). Thus,
inactivation of the EGFR and its signalling pathway was suggested.
As previously stated, the production of many growth factors and
cytokines are well known in anaplastic thyroid cancer. The
production of these molecules in cancer cells was also suggested
to correlate with the highly malignant nature of anaplastic thyroid
cancer (Yoshida et al, 1994; Ogisawa et al, 2002). We thought that
there might be a number of activated growth-stimulating path-
ways, other than the EGF–EGFR pathway, which must contribute
to the growth of anaplastic cancer cells in conditions with FBS
containing many growth factors. However, in the conditions of
activating EGFR with adding EGF in the medium, complete growth
inhibition with gefitinib could be demonstrated for EGFR-
transmitted signal transduction pathways. Previous preclinical
studies have relied on MAPK or Akt activity, representing
preserved functional signals from EGFR activation, as a parameter
of tumour response to gefitinib treatment (Moasser et al, 2001;
Moulder et al, 2001; Ono et al, 2004). Activating mutation in the
tyrosine kinase domain of EGFR has also been suggested recently
to contribute to the responsiveness of NSCLC (Lynch et al, 2004).
Still, the mechanism involving the efficacy of gefitinib is not fully
understood and controversial results are also reported (Campiglio
et al, 2004). In the present study, overexpression of EGFR and
preservation of its signal transduction pathways, phosphorylation
of ERK-1/2 and Akt, were demonstrated in a cell line that
responded well to gefitinib. Our results showed that preservation
of the EGFR-mediated signal transduction pathway is a necessary
condition for EGFR molecular-targeted therapy with gefitinib in
anaplastic thyroid cancer cell lines.
Furthermore, gefitinib treatment displayed antitumour activity
in tumour-bearing mice. We could demonstrate a dramatic growth
suppressive effect of gefitinib on the xenograft of the ACT-1 cells,
which highly expressed EGFR, but not on that of the OCUT-2,
expressing low level of EGFR. The results were similar to that in ‘in
virto’ experiment with EGFR activation. These results clearly
suggested that the effect of gefitinib on the xenograft was a specific
reaction with EGFR on the cells. The efficacy of oral administration
of gefitinib is demonstrated much more effectively in vivo
compared with in vitro data. As stated in the results, immuno-
reactivity of EGFR was diminished in the xenograft of gefitinib-
treated mice, suggesting that the gefitinib-resistance potential is
low in EGFR-expressing cells. We not only found the effect of
gefitinib on the EGFR-overexpressing cancer cells, but also found
it on tumour vessels of the xenograft of ACT-1 cells. Growth and
metastasis of cancer require several processes; angiogenesis plays a
key role (Blood and Zetter, 1990; Hart and Saini, 1992), and it is
well known that EGFR signalling pathways have an important role
in the regulation of angiogenesis (Bruns et al, 2000; Ciardiello et al,
2001; Asakuma et al, 2004). Hirata et al reported that the
antiangiogenic effect of gefitinib in the vascular endothelial cells
of neovasculature is partly attributable to direct inhibition of EGFR
activation, and that endothelial cells in malignant tumours play a
critical role in the therapeutic efficacy of gefitinib (Asakuma et al,
2004; Hirata et al, 2004). We also demonstrated the change in
tumour vessels in the xenograft after gefitinib treatment. The
inhibition of tumour neovasculature might be one of the reasons
that we obtained more significant data from the in vivo study. Still,
the inhibition of the tumour neovasculature was hardly observed
in the xenograft of OCUT-2 cells. Thus, direct effect of gefitinib in
the vascular endothelial cells of neovasculature was not enough to
explain our results. Expression of vascular endothelial growth
factor (VEGF), a strong growth factor for tumour neovasculature,
from cancer cells was reported to suppressed after gefitinib
treatment (Ciardiello et al, 2001). We also found that a significant
suppression of VEGF secretion from ACT-1 cells after gefitinib
treatment (preliminary data, not shown). Thus, the inhibitory
effect of the tumour neovascuature was suggested to be displayed
not only a direct but also VEGF-mediated indirect effect of
gefinitib, as suggested in previous reports (Hirata et al, 2002;
Asakuma et al, 2004). Further studies should be necessary to
clarify the mechanism of the antitumour effect of gefitinib
including tumour neovasculature.
Since anaplastic thyroid cancer has a very poor prognosis, a
dramatic effect might not be expected from monotherapy with
gefitinib in the clinical setting. A combination or a sequential
therapy with chemo-, radio- and molecular-targeted-therapy could
give a new strategy for highly malignant, chemo- and radio-
resistant anaplastic cancer. In conclusion, this study showed the
inhibition of EGFR-mediated cell proliferation and the inhibition
of tumour angiogenesis by gefitinib in anaplastic thyroid cancer
cell lines. This is the first report to describe the potential of EGFR
molecular-targeted therapy for treating anaplastic thyroid cancer.
Our results suggest that the antitumour effects of gefitinib might
offer a new therapeutic approach in anaplastic thyroid carcinoma
when functional expression of EGFR is observed.
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